Business
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces it has Filed an Application with NASDAQ to Uplist to the NASDAQ Global Market from the NASDAQ Capital Market
Management believes uplisting has the potential to provide shareholders with improved liquidityRequires NRx Pharmaceuticals to meet certain listing
About this update from Nrx Pharmaceuticals, Inc.
[{"type":"text","content":"Management believes uplisting has the potential to provide shareholders with improved liquidityRequires NRx Pharmaceuticals to meet certain listing requirementsCompany has advised NASDAQ that current shares outstanding is 15.7 millionWILMINGTON, Del., Jan. 13, 2025 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) (\"NRx\", the \"Company\"), a clinical-stage biopharmaceutical company, today announced it has applied to NASDAQ to uplist the Company's securities to the NASDAQ Global Market (NASDAQ GM).\n\n \n \n \n \n \n \n\n \nListing on the NASDAQ Global Market requires the Company to meet published requirements to successfully list on the NASDAQ Global Market, including maintaining a market value of listed securities (MVLS) above $75 million and a minimum bid price of at least $4.00 for 90 consecutive trading days. The Company has advised NASDAQ that it currently has 15.7 million outstanding shares of common stock, which will inform the calculation of the Company's market capitalization.\n\"We have applied for this uplisting to the NASDAQ Global Market, which is subject to meeting published listing requirements, with the goals of enhancing liquidity for NRx shareholders and meeting the investment requirements of institutional funds that require listing on the Global Market,\" said Dr. Jonathan Javitt, Founder, Chairman and CEO. \"Our aim remains to address suicidal depression and PTSD in the US and elsewhere, and to bring hope to life.\"\nAbout NRx Pharmaceuticals, Inc.\nNRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx plans to file an NDA for Accelerated Approval for NRX-101 in patients with bipolar depression and suicidality or akathisia. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.\nNRx has recently announced initiation of filing a New Drug Application for NRX-100 (IV ketamine) for the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the...